Hepion completes Gravitas deal as Hepion Pharmaceuticals stock adds two programs

Published on 10/16/2026 at 00:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hepion paid USD 2.00 million and issued 25.00 million shares. Hepion Pharmaceuticals stock now covers three programs after the October 6, 2026 closing.

Corporate changes and asset count

Hepion completed the Gravitas acquisition on October 6, 2026, adding two licensed programs.
The transaction included USD 2.00 million in cash and 25.00 million common shares.
Sireesh Appajosyula became chief executive officer on October 9, 2026, with Hepion's portfolio reaching three programs.

HEPA, US4268974015, Illustration mit AI erstellt.

Hepion Pharmaceuticals (ISIN US4268974015) completed its acquisition of Gravitas Life Sciences on October 6, 2026, adding two licensed therapeutic programs. The transaction included USD 2.00 million in cash and 25.00 million common shares, according to StockTitan.

Two programs expand the portfolio

The acquisition made Gravitas a wholly owned subsidiary and brought GV104 and GV023 into Hepion's portfolio. GV104 is a clinical-stage buccal film program for temporary prophylaxis related to opioid exposure, while GV023 is an oral formulation of infliximab in preclinical development, according to Yahoo Finance.

The transaction also changes Hepion's development profile. The company now describes a three-program portfolio spanning therapeutics and diagnostics, with its circulating tumor RNA diagnostic adding a third asset to the two Gravitas programs. That count is a concrete comparison with the pre-acquisition structure described in the October 14, 2026 corporate update.

What changed in the leadership?

Hepion's board appointed Sireesh Appajosyula as chief executive officer and Gary Stetz as chief financial officer, effective October 9, 2026. Appajosyula previously led Gravitas, while Stetz had served as Hepion's interim chief executive officer, according to the filed report linked by StockTitan.

Three dated steps define the deal

On October 1, 2026, Hepion increased its authorized common shares to 750,000,000. On October 6, 2026, it completed the Gravitas acquisition for USD 2.00 million in cash and 25,000,000 shares. On October 9, 2026, the board appointed Appajosyula chief executive officer, completing the current sequence of corporate changes.

Stock trades at a low level

Hepion last traded at USD 0.09 on October 15, 2026, on the OTCQB, with a session price of USD 0.07 recorded as the previous close in the market quote. The company therefore enters the integration phase with a small quoted equity value and a portfolio whose next milestones are development and manufacturing work.